Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly FCF Margin of 26.07% in Q1 2026, up 286.91% on a QoQ basis from 6.74% in Q4 2025, and up 491.0% year-over-year from 4.41% in Q1 2025.
Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed FCF Margin across 18 years of filings, most recently posting 26.07% for Q1 2026.
- Quarterly FCF Margin rose 491.0% year-over-year to 26.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.66% (up 250.0% YoY) and the FY2025 annual result came in at 22.51%, up 543.0% from the prior year.
- FCF Margin improved to 26.07% in Q1 2026, from 6.74% in the prior quarter.
- Over five years, FCF Margin peaked at 43.84% in Q3 2025 and troughed at 16.5% in Q1 2023.
- A 5-year average of 12.17% and a median of 13.68% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 3240 bps — and 2024, when it soared 2245 bps.
- Tracing BMRN's FCF Margin over 5 years: stood at 5.38% in 2022, then jumped by 96 bps to 0.22% in 2023, then jumped by 10116 bps to 22.23% in 2024, then slumped by 70 bps to 6.74% in 2025, then jumped by 287 bps to 26.07% in 2026.
- Business Quant data shows BMRN's FCF Margin at 26.07% in Q1 2026, 6.74% in Q4 2025, and 43.84% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 26.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.07% |
| Dec 31, 2025 | 6.74% |
| Sep 30, 2025 | 43.84% |
| Jun 30, 2025 | 20.37% |
| Mar 31, 2025 | 21.15% |
| Dec 31, 2024 | 22.23% |
| Sep 30, 2024 | 27.22% |
| Jun 30, 2024 | 13.68% |
| Mar 31, 2024 | 3.22% |
| Dec 31, 2023 | -0.22% |
| Sep 30, 2023 | 19.59% |
| Jun 30, 2023 | 8.14% |
| Mar 31, 2023 | -16.50% |
| Dec 31, 2022 | -5.38% |
| Sep 30, 2022 | 25.53% |
| Jun 30, 2022 | 5.45% |
| Mar 31, 2022 | -14.30% |
| Dec 31, 2021 | -3.90% |
| Sep 30, 2021 | 19.16% |
| Jun 30, 2021 | 12.00% |